北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于迪瑞医疗科技股份有限公司 2023 年年度股东大会的 法律意见书 国枫律股字[2024]A0181 号 致：迪瑞医疗科技股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见证 贵公司 2023 年年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》（以下简称 "《股东大会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证券法 律业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证券法 律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《迪瑞医疗科技股份 有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集与召开程序、召 集人资格、出席会议人员资格、会议表决程序及表决结果等事宜，出具本法律意见 ...

证券代码：300396 证券简称：迪瑞医疗 公告编号：2024-027 迪瑞医疗科技股份有限公司 关于减少注册资本暨债权人通知的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 迪瑞医疗科技股份有限公司（以下简称"公司"）于 2024 年 5 月 10 日召开 了 2023 年年度股东大会，审议通过了《关于 2021 年限制性股票激励计划第三个 解除限售期解除限售条件未成就暨回购注销限制性股票的议案》《关于 2022 年 限制性股票激励计划第二个解除限售期解除限售条件未成就暨回购注销限制性 股票的议案》《关于减少公司注册资本的议案》等议案。具体内容详见公司在巨 潮资讯网（www.cninfo.com.cn）披露的相关公告。 一、公司减少注册资本情况说明 二、修改公司章程的情况说明 公司根据上述情况，需要对《公司章程》相应条款进行修订，涉及减少注册 资本和总股本主要具体修订内容如下： | 修订前 | 修订后 | | --- | --- | | 第六条 公司注册资本为人民币274,565,911 | 第六条 公司注册资本为人民币 272,700,161 | | ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：300396 证券简称：迪瑞医疗 公告编号：2024-026 迪瑞医疗科技股份有限公司 2023 年年度股东大会决议公告 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会未涉及变更前次股东大会决议； 一、会议召开和出席情况 公司于 2024 年 04 月 19 日发出《关于召开 2023 年年度股东大会的通知》 （详见中国证监会指定的创业板信息披露网站 http://www.cninfo.com.cn）。 1、会议召开时间：2024 年 05 月 10 日 14:00 2、会议召开地点：公司会议室 3、会议召开方式：采取现场投票与网络投票相结合的方式。现场会议召开 时间：2024 年 05 月 10 日（星期五）14:00。网络投票时间：2024 年 05 月 10 日。 其中，通过交易系统进行网络投票的时间为：2024 年 05 月 10 日（星期五）9:15— 9:25、9:30-11:30 和 13:00—15:00；通过互联网投票系统投票的具体时间为：2024 年 05 月 ...

证 券 研 究 报 告 夯实国内业务，加速扩展海外市场 目标价：35 元 公司发布财报。23 年公司营业收入 13.78 亿元（+12.96%），归母净利润 2.76 亿元（+5.26%），扣非净利润 2.62 亿元（+5.36%）。24Q1 公司营业收入 6.63 亿 元（+99.60%），归母净利润 1.22 亿元（+56.73%），扣非净利润 1.19 亿元 （+55.53%）。 评论： | --- | --- | --- | --- | --- | |----------------------------------|-------|-------------------|-----------------------------|-------| | | 2023A | 2024E | 2025E | 2026E | | 营业总收入 ( 百万 ) | 1,378 | 2,151 | 3,013 | 3,776 | | 同比增速 (%) | 13.0% | 56.1% | 40.1% | 25.3% | | 归母净利润 ( 百万 ) | 276 | 431 | 606 | 764 | | 同比增速 ...

Investment Rating - The report maintains a rating of "Buy" for Dirui Medical, with a target price raised to 31.00 CNY from the previous 29.50 CNY, while the current price is 24.21 CNY [3][22]. Core Insights - The company's revenue for 2023 reached 1.378 billion CNY, reflecting a growth of 12.95%, while the net profit attributable to shareholders was 276 million CNY, up by 5.30% [22]. - The report highlights that the delivery schedule has caused quarterly fluctuations in performance, with Q4 2023 revenue at 329 million CNY, down 21.12%, and Q1 2024 revenue expected to rise significantly to 663 million CNY, an increase of 99.60% [22]. - Domestic market installations are actively advancing, with expectations for reagent sales to increase, supported by enhanced marketing efforts and product installations in hospitals [22]. - The international market is also seeing increased investment and localization efforts, with notable growth in countries like Russia, Indonesia, and India, contributing to a 31.61% increase in international revenue to 547 million CNY in 2023 [22]. Financial Summary - For 2022, the company reported a revenue of 1.22 billion CNY, with projections for 2023 at 1.378 billion CNY, and expected growth to 2.285 billion CNY in 2024, representing a 66% increase [2]. - The operating profit (EBIT) for 2023 is projected at 251 million CNY, with a significant increase to 447 million CNY expected in 2024 [2]. - The net profit attributable to shareholders is forecasted to grow from 276 million CNY in 2023 to 424 million CNY in 2024, marking a 54% increase [2]. Profitability and Valuation Metrics - The operating profit margin is expected to stabilize around 19.6% in 2024, with a net asset return rate projected to increase to 18.5% [2]. - The report indicates a PE ratio of 16.07 for 2024, suggesting a favorable valuation compared to historical performance [2].

Investment Rating - The report maintains a "Buy" rating for the company [4][14]. Core Insights - The company reported a revenue of 1.378 billion yuan in 2023, a year-on-year increase of 12.96%, and a net profit of 275.59 million yuan, up 5.26% year-on-year. In Q1 2024, revenue surged to 663 million yuan, reflecting a 99.60% year-on-year growth, with net profit reaching 122 million yuan, a 56.73% increase [2][4]. - The company is focusing on enhancing channel capabilities and expects significant growth in reagent sales, supported by a series of measures to empower distribution channels and optimize sales teams [3][7]. - The international market is showing promising growth, with revenue from overseas markets increasing by 31.61% in 2023, contributing to 39.7% of total revenue. The company is implementing a large customer strategy and local management upgrades to drive this growth [3][8]. Financial Performance Summary - In 2023, the company achieved a gross margin of 50.53%, with a net profit margin of 20%. The revenue growth rates for 2024 and 2025 are projected at 67.74% and 31.36%, respectively, with net profit growth rates of 57.25% and 31.54% [4][8][12]. - The company's revenue forecast for 2024 and 2025 has been adjusted to 2.311 billion yuan and 3.036 billion yuan, respectively, with net profit forecasts of 433.36 million yuan and 570.03 million yuan [4][5]. - The report highlights a significant increase in earnings per share (EPS), projected to rise from 1.00 yuan in 2023 to 2.08 yuan in 2025 [5][13].

Investment Rating - The report maintains a "Buy" rating for the company, expecting the stock price to outperform the Shanghai Composite Index by more than 20% in the next six months [32]. Core Views - The company achieved a revenue of 1.378 billion yuan in 2023, representing a year-on-year growth of 12.96%, and a net profit attributable to shareholders of 276 million yuan, up 5.26% year-on-year. The growth rate has slowed down mainly due to the revenue recognition schedule, with some overseas income deferred to Q1 2024 [5][38]. - The company’s instrument business is expected to maintain steady growth, while the reagent business is anticipated to see significant expansion starting in 2024. Projected revenues for 2024-2026 are 2.102 billion, 2.599 billion, and 3.190 billion yuan, with corresponding net profits of 400 million, 492 million, and 608 million yuan [9][39]. Summary by Sections Financial Performance - In 2023, the company’s instrument business generated 821 million yuan in revenue, a year-on-year increase of 19.89%, accounting for 59.61% of total revenue. The reagent business brought in 550 million yuan, growing 4.62% year-on-year, making up 39.94% of total revenue [21]. - The company’s gross margin for the year was 50.53%, down 1.46 percentage points, while the net margin was 20.00%, down 1.45 percentage points. The sales expense ratio increased to 18.17%, reflecting increased spending to capture market share [5]. Market Expansion - The company has been enhancing its overseas sales system, achieving rapid business growth. In 2023, domestic revenue was 831 million yuan, up 3.89%, while overseas revenue reached 547 million yuan, a 32.96% increase [40]. - The company has established a comprehensive sales and service network globally, with products sold in over 120 countries, indicating a strong potential for continued overseas market expansion [40].

Investment Rating - The report maintains a "Buy" rating for the company in 2024 [7] Core Views - The company achieved a significant revenue growth of 55.53% year-on-year in Q1 2024, with total revenue reaching 1.378 billion yuan and a net profit attributable to shareholders of 276 million yuan, marking a 99.60% increase year-on-year [7][8] - The report highlights the company's strong performance in the medical device sector, with a focus on enhancing sales capabilities and expanding into global markets [7] - The company is expected to continue its growth trajectory, with projected revenues of 2.063 billion yuan in 2024, reflecting a growth rate of 49.7% [8] Summary by Sections Financial Performance - In Q1 2024, the company reported a revenue of 1.378 billion yuan, a year-on-year increase of 55.53%, and a net profit of 276 million yuan, up 99.60% year-on-year [7] - The company’s revenue from instrument sales grew by 4.62% in 2023, while reagent sales growth was slower, indicating a need for improvement in reagent performance [7] Market Position and Strategy - The company has established subsidiaries in Thailand, Indonesia, and Russia to promote local production of instruments and reagents, which is expected to drive rapid growth in overseas markets [7] - The report emphasizes the importance of optimizing assessment mechanisms to enhance sales performance and accelerate reagent growth [7] Earnings Forecast - The company is projected to achieve revenues of 2.063 billion yuan in 2024, with net profits expected to reach 402 million yuan, reflecting a growth rate of 45.8% [8] - Earnings per share (EPS) are forecasted to be 1.46 yuan in 2024, with continued growth anticipated in subsequent years [8]

迪瑞医疗科技股份有限公司 关于控股股东部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 迪瑞医疗科技股份有限公司（以下简称"公司"）于近日接到公司控股股东 深圳市华德欣润股权投资企业（有限合伙）（以下简称"华德欣润"）的通知，获 悉其所持有本公司的部分股份办理了质押手续，具体事项如下： | | 是否为 第一大 | 本次质押 | 占其 所持 | 占公司 | 是否 | 是否 为补 | 质押开 | | 质押到期 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 股东及 | 股份数量 | | 总股本 | 为限 | | | | | | 质权人 | 质权用途 | | 名称 | | | 股份 | | | 充质 | 始日期 | | 日期 | | | | | | 一致行 | (股) | 比例 | 比例 | 售股 | 押 | | | | | | | | | 动人 | | | | | | | | | | | | | 华德 | ...

证券代码：300396 证券简称：迪瑞医疗 公告编号：2024-017 迪瑞医疗科技股份有限公司 关于公司续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 迪瑞医疗科技股份有限公司（以下简称"公司"）于 2024 年 4 月 17 日召开 的第六届董事会第二次会议和第六届监事会第二次会议，审议通过了《关于续聘 2024 年度审计机构的议案》，公司拟聘任大信会计师事务所（特殊普通合伙） （以下简称"大信所"）为公司 2024 年度审计机构，聘期为一年。2024 年度审 计费用由董事会提请股东大会授权公司管理层根据具体审计要求和审计范围与 大信所所协商确定，本事项需提交公司股东大会审议批准。现将相关情况公告如 下： 机构性质：特殊普通合伙企业 注册地址：北京市海淀区知春路 1 号学院国际大厦 22 层 统一社会信用代码：91110108590611484C 业务资质：具备会计师事务所执业证书 是否曾从事过证券服务业务：是 一、拟续聘会计师事务所事项的情况说明 大信会计师事务所具备会计师事务所执业证书和证券、期货相关业务许可证， 该公司在执业过 ...